Jiangsu Hengrui Medicine Company Ltd.

Shanghai Hengrui Pharmaceutical Co., Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Changzhou Hansoh Pharmaceutical Co., Ltd.

Suzhou Suncediabiopharmaeuticals Co., Ltd.

Hansoh (shanghai) Healthtech Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Lianshan Zhang

Weikang Tao

Guoqing Cao

Piaoyang Sun

Xin Ye

Qiyue Hu

Xiangdong Qu

Changyong Yang

Dongbing Cui

Jiahua Jiang

Lei Zhang

Yayuan Fu

Jijun Yuan

Jiajian Liu

Cheng Liao

Yali Wang

Yong Guo

Shaoyu Xu

Xing Sun

Li Yang

Ling L Zhang

Ting Ting Zhang

Liuqing Yang

Xiaohua Wang

Zhuoxiao Cao

Jinming Gu

Jindong Liang

Zhibin Xu

Xiaoxing Huang

Xueming Qian

Fei Teng

Jufang Lin

Houcong Jin

Jie Li

Ying Zhang

Zhen Zhang

Fanglong Yang

Zhen Yan

Changan Sun

Yan Fang

Yifang Wang

Pingping Wang

Ling Zhang

Jianyan Xu

Guiyang Jiang

Xiaohua Wu

Ang Li

Qing Yang

Hengli Yuan

Bei Yuan

Zupeng Xu

Quanren Wang

Dingwei Ye

Dong Ma

Ke Ma

Junzhuan Qiu

Jianjun Zou

Ziyong Sun

Jiping Zha

Jingping Wei

Haoying Zhang

Kan Chen

Chunqian Fang

Lin Shen

Jing Gao

Shude Yan

Jifang Gong

Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating cancers.

Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers

The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.

Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors

The present invention provides an anti-ox40 antibody, an antigen-binding fragment thereof, and the pharmaceutical use. Further, the present application provides a chimeric antibody and a humanized antibody, the chimeric antibody and the humanized antibody comprising a CDR region from the anti-OX40 antibody and the antigen-binding fragment thereof, and also provides a pharmaceutical composition comprising the anti-OX40 antibody and the antigen-binding fragment thereof, and the use thereof as a drug for treating cancers.

Anti-OX40 antibody, antigen-binding fragment thereof, and the pharmaceutical use

The present disclosure relates to a human IL-4R binding antibody, an antigen binding fragment thereof, and a medical use thereof. Provided are a chimeric antibody and a humanized antibody, including a CDR region from a human IL-4R binding antibody and an antigen binding fragment thereof, a pharmaceutical composition including the human IL-4R binding antibody and the antigen binding fragment thereof, and a use thereof as a drug treating allergic disease. Also provided is a use of the humanized antibody IL-4R binding antibody in preparing a drug used for treating IL-4R mediated diseases or illnesses.

Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof

Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.

LAG-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof

The present invention relates to a PD-L1 antibody, antigen-binding fragments, and medical application thereof. Further, the present invention relates to chimeric antibodies and humanized antibodies comprising the CDR regions of the present PD-L1 antibody, as well as a pharmaceutical composition comprising the present PD-L1 antibody and the antigen-binding fragments thereof, and their use as anti-cancer drugs. In particular, the present invention relates to a humanized PD-L1 antibody and its use in preparation of a medicament for the treatment of PD-L1 mediated disease or disorder.

PD-L1 antibody, antigen-binding fragment thereof and medical application thereof

An interleukin 15 (IL-15) protein complex is provided. The IL-15 protein complex includes soluble fusion proteins (I) and (II), wherein the fusion protein (I) is an IL-15 polypeptide or a functional fragment thereof, and the soluble fusion protein (II) is an IL-15R&#x3b1; polypeptide or a functional fragment thereof. The soluble fusion protein (I) has at least one amino acid residue mutated to a cysteine (Cys) residue, which pairs with a corresponding mutated Cys residue on the soluble fusion protein (II), or vice versa, to form one or more disulfide bonds. The IL-15 protein complex can be used for tumor therapy.

Interleukin 15 protein complex and use thereof

A B7-H3 antibody, an antigen-binding fragment thereof and a medical use thereof are provided. Furthermore, a pharmaceutical composition containing the B7-H3 antibody or antigen-binding fragment thereof, and the use thereof as a medicament are provided. In particular, a use of a human B7-H3 antibody or antigen-binding fragment thereof for the manufacture of a medicament for the treatment of a B7-H3-associated disease or condition are described.

B7-H3 antibody, antigen-binding fragment thereof and medical use thereof

Provided are an anti-CD40 antibody, an antigen binding fragment thereof, and a medical use thereof. Also provided are a chimeric antibody and a humanized antibody including a CDR region of the anti-CD40 antibody, a pharmaceutical composition including the human anti-CD40 antibody and the antigen binding fragment thereof, and an application thereof as an anti-cancer drug. In particular, provided are a humanized anti-CD40 antibody, and an application thereof in preparation of a drug to treat a CD40-mediated disease or disorder.

Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof

Disclosed is the use of a KOR agonist in combination with a MOR agonist in preparing a drug for treating pain. The KOR agonist is selected from a compound as shown in the general formula (I), and the MOR agonist is selected from a compound as shown in the general formula (II), wherein the definitions of each substituent in the general formula (I) and (II) are the same as defined in the description. 

Use of KOR agonist in combination with MOR agonist in preparing drug for treating pain

The present invention provides a human PD-1 antibody, an antigen-binding fragment thereof, and medical use thereof, and further provides a chimeric antibody and humanized antibodies comprising a complementarity-determining region (CDR) of the antibody, a pharmaceutical composition comprising the human PD-1 antibody and the antigen-binding fragment thereof, and use of the antibody in preparing medicines for treating diseases or disorders.

PD-1 antibody, antigen-binding fragment thereof, and medical application thereof

This application describes a use of an EZH2 inhibitor combined with a BTK inhibitor in preparing a drug for treating a tumor is described.

Use of EZH2 inhibitor combined with BTK inhibitor in preparing drug for treating tumor

Growing community of inventors

Shanghai, China

Lianshan Zhang